The objective of this consensus paper is to establish clinical recommendations for decisions in (a) surgical interventions in HER2-negative eBC carrying BRCA germline pathogenic variants, (b) treatment sequencing in HR-positive HER2-negative eBC or early TNBC (eTNBC) that are BRCA germline pathogenic variants, and (c) management of metastatic HER2-negative BC carrying BRCA germline pathogenic variants. This evidence concerns the gene ERBB2 and breast cancer.